p38MAPK Signaling Pathway in Osteoarthritis: Pathological and Therapeutic Aspects

References

• Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759. doi:10.1016/S0140-6736(19)30417-9
   PubMed Web of Science ®Google Scholar
• Glyn-Jones S, Palmer AJR, Agricola R, et al. Osteoarthritis. Lancet. 2015;386(9991):376–387. doi:10.1016/S0140-6736(14)60802-3
   PubMed Web of Science ®Google Scholar
• James Spencer L, Abate D, Abate Kalkidan H, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625–635. doi:10.1038/nrrheum.2010.159
   PubMed Web of Science ®Google Scholar
• Palazzo C, Nguyen C, Lefevre-Colau M, Rannou F, Poiraudeau S. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):134–138. doi:10.1016/j.rehab.2016.01.006
   PubMed Web of Science ®Google Scholar
• Le Graverand-gastineau MH. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets. 2010;11(5):528. doi:10.2174/138945010791011893
   PubMed Web of Science ®Google Scholar
• Zhang W, Ouyang H, Dass CR, Xu J. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016;4(1):15040. doi:10.1038/boneres.2015.40
   PubMed Web of Science ®Google Scholar
• Santana DC, Emara AK, Orr MN, et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina. 2020;56(9):416. doi:10.3390/medicina56090416
   PubMed Web of Science ®Google Scholar
• SooHoo NF. Factors predicting complication rates following total knee replacement. J Bone Joint Surg. 2006;88(3):480.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhang C, Yi Z, Lan C. Explore the variation of MMP3, JNK, p38 MAPKs, and autophagy at the early stage of osteoarthritis. Iubmb Life. 2016;68(4):293–302. doi:10.1002/iub.1482
   PubMed Web of Science ®Google Scholar
• Gao T, Hu Q, Hu X, et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Cancer Lett. 2019;445:11–23. doi:10.1016/j.canlet.2018.12.016
   PubMed Web of Science ®Google Scholar
• Liao C, Wang S, Zhu S, et al. Advanced oxidation protein products increase TNF-α and IL-1β expression in chondrocytes via NADPH oxidase 4 and accelerate cartilage degeneration in osteoarthritis progression. Redox Biol. 2020;28:101306. doi:10.1016/j.redox.2019.101306
   PubMed Web of Science ®Google Scholar
• Shan W, Cheng C, Huang W, et al. Angiopoietin-like 2 upregulation promotes human chondrocyte injury via NF-κB and p38/MAPK signaling pathway. J Bone Miner Metab. 2019;37(6):976–986. doi:10.1007/s00774-019-01016-w
   PubMed Web of Science ®Google Scholar
• Ma N, Teng X, Zheng Q, Chen P. The regulatory mechanism of p38/MAPK in the chondrogenic differentiation from bone marrow mesenchymal stem cells. J Orthop Surg Res. 2019;14(1):434. doi:10.1186/s13018-019-1505-2
   PubMed Web of Science ®Google Scholar
• Sun H, Hu K, Yin Z. Inhibition of the p38-MAPK signaling pathway suppresses the apoptosis and expression of proinflammatory cytokines in human osteoarthritis chondrocytes. Cytokine. 2017;90:135–143. doi:10.1016/j.cyto.2016.11.002
   PubMed Web of Science ®Google Scholar
• Brewster JL, de Valoir T, Dwyer ND, Winter E, Gustin MC. An osmosensing signal transduction pathway in yeast. Science. 1993;259(5102):1760–1763. doi:10.1126/science.7681220
   PubMed Web of Science ®Google Scholar
• Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265(5173):808–811. doi:10.1126/science.7914033
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–1912. doi:10.1126/science.1072682
   PubMed Web of Science ®Google Scholar
• Morazzani M, de Carvalho DD, Kovacic H, et al. Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: implication of ROS-P38 MAPK-integrin ?2?1 pathway. Int J Cancer. 2004;110(6):788–799. doi:10.1002/ijc.20198
   PubMed Web of Science ®Google Scholar
• Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem. 1997;272(38):23668–23674. doi:10.1074/jbc.272.38.23668
   PubMed Web of Science ®Google Scholar
• Liu J, Han L, Li B, et al. F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6). J Biol Chem. 2014;289(31):21508–21518. doi:10.1074/jbc.M114.560342
   PubMed Web of Science ®Google Scholar
• Sanderson TM, Hogg EL, Collingridge GL, Corrêa SAL. Hippocampal metabotropic glutamate receptor long-term depression in health and disease: focus on mitogen-activated protein kinase pathways. J Neurochem. 2016;139:200–214. doi:10.1111/jnc.13592
   PubMed Web of Science ®Google Scholar
• Kojonazarov B, Novoyatleva T, Boehm M, et al. p38 MAPK inhibition improves heart function in pressure-loaded right ventricular hypertrophy. Am J Resp Cell Mol. 2017;57(5):603–614. doi:10.1165/rcmb.2016-0374OC
   PubMed Web of Science ®Google Scholar
• Xu Q, Fang H, Zhao L, et al. Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathway. Bioscience Rep. 2019;39(3). doi:10.1042/BSR20182462
   Web of Science ®Google Scholar
• Kita K, Sugita K, Sato C, et al. Extracellular release of annexin A2 is enhanced upon oxidative stress response via the p38 MAPK pathway after low-dose X-ray irradiation. Radiat Res. 2016;186(1):79. doi:10.1667/RR14277.1
   PubMed Web of Science ®Google Scholar
• Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000;47(2–3):185–201. doi:10.1016/S0162-3109(00)00206-X
   PubMed Web of Science ®Google Scholar
• Martín-Segura A, Casadomé-Perales Á, Fazzari P, et al. Aging increases hippocampal DUSP2 by a membrane cholesterol loss-mediated RTK/p38MAPK activation mechanism. Front Neurol. 2019;10:675. doi:10.3389/fneur.2019.00675
   PubMed Web of Science ®Google Scholar
• Brichkina A, Bulavin DV. Cancer suppression by systemic inactivation of p38MAPK. Oncotarget. 2017;8(9):14275–14276. doi:10.18632/oncotarget.15293
   PubMedGoogle Scholar
• Moreno-Cugnon L, Arrizabalaga O, Llarena I, Matheu A. Elevated p38MAPK activity promotes neural stem cell aging. Aging (Albany NY). 2020;12(7):6030-6036. doi:10.18632/aging.102994
   Google Scholar
• Huang J, Liu C, Ming X, Yang Z. Inhibition of p38mapk reduces adipose tissue inflammation in aging mediated by arginase-II. Pharmacology. 2020;105(9–10):491–504. doi:10.1159/000507635
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang P, Ma X. Rab7 delays intervertebral disc degeneration through the inhibition of the p38MAPK pathway. Biochem Bioph Res Commun. 2019;514(3):835–841. doi:10.1016/j.bbrc.2019.04.184
   PubMed Web of Science ®Google Scholar
• Kheiri G, Dolatshahi M, Rahmani F, Rezaei N. Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy. Rev Neurosci. 2018;30(1):9–30. doi:10.1515/revneuro-2018-0008
   PubMed Web of Science ®Google Scholar
• Sherwood J. Osteoarthritis year in review 2018: biology. Osteoarthr Cartilage. 2019;27(3):365–370. doi:10.1016/j.joca.2018.10.005
   PubMed Web of Science ®Google Scholar
• Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl. 2017;147:1–73.
   PubMed Web of Science ®Google Scholar
• Mehana EE, Khafaga AF, El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis: an updated review. Life Sci. 2019;234:116786. doi:10.1016/j.lfs.2019.116786
   PubMed Web of Science ®Google Scholar
• Slovacek H, Khanna R, Poredos P, et al. Interrelationship of osteopontin, MMP-9 and ADAMTS4 in patients with osteoarthritis undergoing total joint arthroplasty. Clin Appl Thrombos Hemostas. 2020;26:107602962096486. doi:10.1177/1076029620964864
   Web of Science ®Google Scholar
• Niu C, Lin S, Yuan L, et al. Upregulation of miR-107 expression following hyperbaric oxygen treatment suppresses HMGB1/RAGE signaling in degenerated human nucleus pulposus cells. Arthritis Res Ther. 2019;21(1):42. doi:10.1186/s13075-019-1830-1
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–573. doi:10.1016/j.cardiores.2005.12.002
   PubMed Web of Science ®Google Scholar
• Yu Z, Xie M, Fan X, Jia J. Interferon alpha2b increases MMP-13 and IL-10 expression in Kupffer cells through MAPK signaling pathways. Hepatogastroenterology. 2015;62(138):350–354.
   PubMedGoogle Scholar
• Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33–42. doi:10.1038/nrrheum.2010.196
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartilage. 2014;22(3):363–388. doi:10.1016/j.joca.2014.01.003
   PubMed Web of Science ®Google Scholar
• Kim J, Yoo J, Kim H. Therapeutics in osteoarthritis based on an understanding of its molecular pathogenesis. Int J Mol Sci. 2018;19(3):674. doi:10.3390/ijms19030674
   PubMed Web of Science ®Google Scholar
• Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Research. 2019;8:934. doi:10.12688/f1000research.18831.1
   Google Scholar
• Liu X, Wang L, Ma C, et al. Exosomes derived from platelet-rich plasma present a novel potential in alleviating knee osteoarthritis by promoting proliferation and inhibiting apoptosis of chondrocyte via Wnt/β-catenin signaling pathway. J Orthop Surg Res. 2019;14(1). doi:10.1186/s13018-019-1529-7
   Web of Science ®Google Scholar
• Fidelix TSA, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Db Syst Rev. 2014;(2):CD005117. doi:10.1002/14651858.CD005117.pub3
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Bliddal H, Blanco FJ, et al. A phaseII TRIAL of lutikizumab, an anti–interleukin‐1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthrit Rheumatol. 2019;71(7):1056–1069. doi:10.1002/art.40840
   PubMed Web of Science ®Google Scholar
• Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth F R. 2018;44:38–50. doi:10.1016/j.cytogfr.2018.10.002
   PubMed Web of Science ®Google Scholar
• Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184–195. doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Wojdasiewicz P, Poniatowski AA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediat Inflamm. 2014;2014:1–19. doi:10.1155/2014/561459
   Web of Science ®Google Scholar
• Han F, Jiang H, Qu W, Rui Y. KLF11 protects chondrocytes via inhibiting p38 MAPK signaling pathway. Eur Rev Med Pharmacol. 2020;24(12):6505.
   PubMed Web of Science ®Google Scholar
• Lei J, Fu Y, Zhuang Y, Zhang K, Lu D. LncRNA SNHG1 alleviates IL-1β-induced osteoarthritis by inhibiting miR-16-5p-mediated p38 MAPK and NF-κB signaling pathways. Bioscience Rep. 2019;39(9). doi:10.1042/BSR20191523
   Web of Science ®Google Scholar
• Cao Z, Liu W, Qu X, et al. miR-296-5p inhibits IL-1β-induced apoptosis and cartilage degradation in human chondrocytes by directly targeting TGF-β1/CTGF/p38MAPK pathway. Cell Cycle. 2020;19(12):1443–1453. doi:10.1080/15384101.2020.1750813
   PubMed Web of Science ®Google Scholar
• Surinkaew S, Kumphune S, Chattipakorn S, Chattipakorn N. Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharm. 2013;61(2):133–141. doi:10.1097/FJC.0b013e318279b7b1
   PubMed Web of Science ®Google Scholar
• Sugiyama N, Kohno M, Yokoyama T. Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Nephrol Dial Transpl. 2012;27(4):1351–1358. doi:10.1093/ndt/gfr550
   PubMed Web of Science ®Google Scholar
• Zhang S, Cao H, Li Y, et al. Metabolic benefits of inhibition of p38α in white adipose tissue in obesity. PLoS Biol. 2018;16(5):e2004225. doi:10.1371/journal.pbio.2004225
   PubMed Web of Science ®Google Scholar
• Lee JK, Kim N. Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules. 2017;22(8):1287. doi:10.3390/molecules22081287
   PubMed Web of Science ®Google Scholar
• Wang S, Ding L, Ji H, et al. The role of p38 MAPK in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17(7):1037. doi:10.3390/ijms17071037
   PubMed Web of Science ®Google Scholar
• Kang S, Kim J, Shin DY. Inhibition of senescence and promotion of the proliferation of chondrocytes from articular cartilage by CsA and FK506 involves inhibition of p38MAPK. Mech Ageing Dev. 2016;153:7–13. doi:10.1016/j.mad.2015.12.002
   PubMed Web of Science ®Google Scholar
• Zhang H, Lin J, Chen J, et al. Effects of Notch/p38MAPK signaling pathway on articular cartilage defect recovery by BMSCs tissue based on the rabbit articular cartilage defect models. Saudi J Biol Sci. 2020;27(3):859–864. doi:10.1016/j.sjbs.2019.12.021
   PubMed Web of Science ®Google Scholar
• Zhou Z, Tang SA, Nie X, et al. Osteoarthritic infrapatellar fat pad aggravates cartilage degradation via activation of p38MAPK and ERK1/2 pathways. Inflamm Res. 2021;70(10–12):1129–1139. doi:10.1007/s00011-021-01503-9
   PubMed Web of Science ®Google Scholar
• Song W, Dong Y, Luo C, Chen Y. p38MAPK family isoform p38α and activating transcription factor 2 are associated with the malignant phenotypes and poor prognosis of patients with ovarian adenocarcinoma. Pathol Res Pract. 2017;213(10):1282–1288. doi:10.1016/j.prp.2017.08.003
   PubMed Web of Science ®Google Scholar
• Chen X, Lv R, Zhang W, et al. Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition. Oncotarget. 2016;7(21):31053–31066. doi:10.18632/oncotarget.8842
   PubMedGoogle Scholar
• Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83(4):345–352. doi:10.1161/01.RES.83.4.345
   PubMed Web of Science ®Google Scholar
• Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. Oncogene. 2006;25(46):6176–6187. doi:10.1038/sj.onc.1209912
   PubMed Web of Science ®Google Scholar
• Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319(5871):1785–1786. doi:10.1126/science.1151651
   PubMed Web of Science ®Google Scholar
• Rasheed Z, Rasheed N, Abdulmonem WA, Khan MI. MicroRNA-125b-5p regulates IL-1β induced inflammatory genes via targeting TRAF6-mediated MAPKs and NF-κB signaling in human osteoarthritic chondrocytes. Sci Rep UK. 2019;9(1):6882. doi:10.1038/s41598-019-42601-3
   PubMed Web of Science ®Google Scholar
• Yuan L, Chang X, Yao W, et al. MiR-214 inhibits knee osteoarthritis in rats through MAPK signaling pathway. Panminerva Med. 2019. doi:10.23736/S0031-0808.19.03716-9
   Google Scholar
• Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364(2):229–233.
   PubMed Web of Science ®Google Scholar
• Morel C, Ibarz G, Oiry C, et al. Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and P38 MAP Kinase. J Biol Chem. 2005;280(22):21384–21393. doi:10.1074/jbc.M408851200
   PubMed Web of Science ®Google Scholar
• Wang G, Pang Z, Chen-Yu Hsu A, et al. Combined treatment with SB203580 and dexamethasone suppresses non-typeable Haemophilus influenzae-induced Th17 inflammation response in murine allergic asthma. Eur J Pharmacol. 2019;862:172623. doi:10.1016/j.ejphar.2019.172623
   PubMed Web of Science ®Google Scholar
• Jin X, Gong P, Li G, Zhang X, Li J. The p38 MAPK inhibitor, SB203580, inhibits cell invasion by Neospora caninum. Parasitol Res. 2017;116(2):813–819. doi:10.1007/s00436-016-5346-1
   PubMed Web of Science ®Google Scholar
• Gao X, Li N, Zhang J. SB203580, a p38MAPK inhibitor, attenuates olfactory dysfunction by inhibiting OSN apoptosis in AR mice (activation and involvement of the p38 mitogen‐activated protein kinase in olfactory sensory neuronal apoptosis of OVA‐induced allergic rhinitis). Brain Behav. 2019;9(6):e01295–n/a. doi:10.1002/brb3.1295
   Web of Science ®Google Scholar
• Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther. 2008;327(3):610–619. doi:10.1124/jpet.108.139006
   PubMed Web of Science ®Google Scholar
• Zhao X, Ning L, Xie Z, et al. The novel p38 inhibitor, pamapimod, inhibits osteoclastogenesis and counteracts estrogen‐dependent bone loss in mice. J Bone Miner Res. 2019;34(5):911–922. doi:10.1002/jbmr.3655
   PubMed Web of Science ®Google Scholar
• Zhang J, Yan C, He W, Wang M, Liu J. Inhibition against p38/MEF2C pathway by Pamapimod protects osteoarthritis chondrocytes hypertrophy. Panminerva Med. 2020. doi:10.23736/S0031-0808.20.04170-1
   Google Scholar
• Zhao C, Gao Y, Song W, et al. An update on the emerging role of resistin on the pathogenesis of osteoarthritis. Mediat Inflamm. 2019;2019:1–8.
   Web of Science ®Google Scholar
• Chen W, Lin C, Kuo S, et al. Resistin enhances VCAM-1 expression and monocyte adhesion in human osteoarthritis synovial fibroblasts by inhibiting miR-381 expression through the PKC, p38, and JNK signaling pathways. Cells-Basel. 2020;9(6):1369. doi:10.3390/cells9061369
   PubMed Web of Science ®Google Scholar
• Huang X, Ni B, Xi Y, et al. Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis. Aging. 2019;11(24):12532–12545. doi:10.18632/aging.102586
   PubMedGoogle Scholar
• Ren C, Liang Z. Piperine alleviates lipopolysaccharide-induced inflammatory injury by down-regulating microRNA-127 in murine chondrogenic ATDC5 cells. Biomed Pharmacother. 2018;103:947–954. doi:10.1016/j.biopha.2018.04.108
   PubMed Web of Science ®Google Scholar
• Fan L, Li M, Cao F, et al. Astragalus polysaccharide ameliorates lipopolysaccharide-induced cell injury in ATDC5 cells via miR-92a/KLF4 mediation. Biomed Pharmacother. 2019;118:109180. doi:10.1016/j.biopha.2019.109180
   PubMed Web of Science ®Google Scholar
• Jin H, Zhang H, Ma T, et al. Resveratrol protects murine chondrogenic ATDC5 cells against LPS-induced inflammatory injury through up-regulating MiR-146b. Cell Physiol Biochem. 2018;47(3):972–980. doi:10.1159/000490141
   PubMedGoogle Scholar
• Li Q, Xing W, Xu X, et al. Tetramethylpyrazine alleviates lipopolysaccharide-induced damage in ATDC5 cells via down-regulating MyD88. Exp Mol Pathol. 2019;111:104317. doi:10.1016/j.yexmp.2019.104317
   PubMed Web of Science ®Google Scholar
• Feng S, Cong H, Ji L. Salvianolic acid A exhibits anti-inflammatory and antiarthritic effects via inhibiting NF-κB and p38/MAPK pathways. Drug Des Devel Ther. 2020;14:1771–1778. doi:10.2147/DDDT.S235857
   PubMed Web of Science ®Google Scholar
• Li H, You Y, Jiang B, et al. Wang-Bi tablet ameliorates DMM-induced knee osteoarthritis through suppressing the activation of p38-MAPK and NF-κB signaling pathways in mice. Evid Based Compl Alt. 2021;2021:1–9. doi:10.1155/2021/2209574
   Web of Science ®Google Scholar
• Yao Y, Wang Y. ATDC5: an excellent in vitro model cell line for skeletal development. J Cell Biochem. 2013;114(6):1223–1229. doi:10.1002/jcb.24467
   PubMed Web of Science ®Google Scholar
• Noguchi H, Miyagi Shiohira C, Nakashima Y, Saitoh I, Watanabe M. Novel cell‐permeable p38‐MAPK inhibitor efficiently prevents porcine islet apoptosis and improves islet graft function. Am J Transplant. 2020;20(5):1296–1308. doi:10.1111/ajt.15740
   PubMed Web of Science ®Google Scholar
• Wagner SJ, Skripchenko A, Seetharaman S, Kurtz J. Amelioration of lesions associated with 24-hour suboptimal platelet storage at 16 °C by a p38MAPK inhibitor, VX-702. Vox Sang. 2015;108(3):226–232. doi:10.1111/vox.12221
   PubMed Web of Science ®Google Scholar
• Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60(5):1232–1241. doi:10.1002/art.24485
   PubMed Web of Science ®Google Scholar
• Shao B, Xu Z, Han B, Su D, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6. doi:10.3389/fphar.2015.00262
   PubMed Web of Science ®Google Scholar
• Ni B, Pei W, Qu Y, et al. MCC950, the NLRP3 inhibitor, protects against cartilage degradation in a mouse model of osteoarthritis. Oxid Med Cell Longev. 2021;2021:1–14.
   Web of Science ®Google Scholar
• Wang H, Shan XB, Qiao YJ. PDK2 promotes chondrogenic differentiation of mesenchymal stem cells by upregulation of Sox6 and activation of JNK/MAPK/ERK pathway. Braz J Med Biol Res. 2017;50(2):e5988–e5988. doi:10.1590/1414-431x20165988
   PubMed Web of Science ®Google Scholar
• Benabdoune H, Rondon E, Shi Q, et al. The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflamm Res. 2016;65(8):635–645. doi:10.1007/s00011-016-0946-x
   PubMed Web of Science ®Google Scholar
• Zheng S, Ren J, Gong S, Qiao F, He J. CTRP9 protects against MIA-induced inflammation and knee cartilage damage by deactivating the MAPK/NF-κB pathway in rats with osteoarthritis. Open Life Sci. 2020;15(1):971–980. doi:10.1515/biol-2020-0105
   PubMed Web of Science ®Google Scholar
• Ito T, Omori K, Rawson J, et al. Improvement of canine islet yield by donor pancreas infusion with a p38MAPK inhibitor. Transplantation. 2008;86(2):321–329. doi:10.1097/TP.0b013e31817ef6c9
   PubMed Web of Science ®Google Scholar
• Bagley MC, Dwyer JE, Baashen M, et al. The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells. Org Biomol Chem. 2016;14(3):947–956. doi:10.1039/C5OB02229K
   PubMed Web of Science ®Google Scholar